Diagnostics

BioNTech says it will know in 2 weeks whether the COVID-19 vaccine it developed with Pfizer works against the new variant rapidly spreading in southern Africa

11/29/2021

BioNTech is testing its COVID vaccine against a rapidly spreading variant, the Financial Times said. The B.1.1.529 variant has been detected in South Africa, Botswana, Hong Kong, and Israel. Excerpt from the Press Release: BioNTech said it’s testing the COVID-19 vaccine it developed with Pfizer against the new variant that appears to have emerged in southern Africa, and that it would know in two weeks…

Read More

Blood Cancer UK partners with RareCan to improve delivery of clinical trials

11/29/2021

Charity Blood Cancer UK has teamed up with oncology company RareCan to support the organisation’s delivery of clinical trials focussed on the prevention, diagnosis, or treatment of rare cancers. Excerpt from the Press Release: Blood cancer The partnership will see Blood Cancer UK join the charity network GIST Cancer UK as RareCan’s partner. The aim…

Read More

Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Detection

11/24/2021

Excerpt from the Press Release: MADISON, Wis. and PHILADELPHIA, Nov. 18, 2021 /PRNewswire/ — Exact Sciences Corp. (NASDAQ: EXAS) today announced an agreement with Jefferson Health (Jefferson) to conduct research on a new blood-based, multi-cancer earlier detection (MCED) test. This unique effort will engage primary care and specialty providers, care coordinators, and patients from diverse populations across the Jefferson enterprise in research that aims…

Read More

Helixmith Announces Phase 3 Study Results of Novel Gene Therapy Treatment for Diabetic Foot Ulcers at 2021 Annual Meeting of Diabetic Foot Ulcer Conference (DFCon)

10/29/2021

Data indicate that gene therapy appears to be effective, particularly in neuroischemic ulcers Excerpt from the Press Release: SAN DIEGO, Oct. 22, 2021 /PRNewswire/ — Helixmith, a gene therapy company based in Seoul, Korea and San Diego, CA, announced today the results of a Phase 3 study for the treatment of diabetic foot ulcers with their novel gene therapy VM202 (Engensis)…

Read More

Kinetic River Corp. Receives First Japanese Patent for Time-Resolved Flow Cytometry

10/08/2021

This issuance expands global protection for Kinetic River’s technologies aimed at expanding the power of flow cytometry Excerpt from the Press Release: MOUNTAIN VIEW, Calif., Oct. 1, 2021 /PRNewswire/ — Kinetic River Corp., a leader in custom flow cytometry instrumentation, announced today having been issued a patent from the Japanese Patent Office covering its innovative technologies…

Read More

Amolyt Pharma Announces Positive Data from Phase 1 Trial of AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting

10/08/2021

Excerpt from the Press Release: LYON, France and CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive results from its Phase 1 clinical trial of AZP-3601, a potential treatment for hypoparathyroidism, at the American Society for Bone…

Read More

Phil Announces Partnership with Impel NeuroPharma in Support of Trudhesa™ (dihydroergotamine mesylate) Nasal Spray for the Acute Treatment of Migraine

10/06/2021

Excerpt from the Press Release: SAN FRANCISCO, Sept. 29, 2021 /PRNewswire/ — Phil, Inc. announces partnership with Impel NeuroPharma, Inc. (NASDAQ: IMPL) in support of Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) to provide technology-powered patient support and distribution services through Phil’s proprietary workflow to enhance the patient’s access to therapy. Trudhesa is indicated for the acute treatment of…

Read More

Recent study in the Journal of Urology shows PredicineCARE urine-based liquid biopsy test provides non-invasive molecular profiling for patients with bladder cancer

10/05/2021

Results from the study utilizing the PredicineCARE liquid biopsy assay evaluate the concordance of somatic alterations identified by standard tissue testing to those identified by analysis of urinary circulating tumor DNA in patients with urothelial bladder cancer. Excerpt from the Press Release: “This study demonstrates the clinical value of urine-based liquid biopsy testing to provide…

Read More

TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer

09/30/2021

– Imaging study confirms the biodistribution of TTX-MC138 in models of metastatic cancer, supporting TransCode’s TTX platform for delivery of RNA targeted therapy to metastatic solid tumors – — eIND submission for TTX-MC138 anticipated in 1Q 2022 to support Phase 0 study in metastatic solid tumors, designed to establish proof of concept for TTX delivery platform — BOSTON–(BUSINESS…

Read More

Iterative Scopes and Crohn’s & Colitis Foundation Announce Partnership to Advance Next-Generation IBD Treatment

09/30/2021

Access to the Foundation’s unparalleled patient data repository will enrich company’s computational endoscopic approaches to biopharmaceutical research and clinical care for IBD CAMBRIDGE, Mass.–(BUSINESS WIRE)–Iterative Scopes, a pioneer in the development of precision-based technologies for treating gastrointestinal diseases, announced today that it has entered into an AI-powered diagnostic tools partnership with the Crohns & Colitis…

Read More